Barclays raises target for Elevance Health stock from USD 457 to USD 469

Published on 10/12/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays raised its target from USD 457 to USD 469 on October 7, 2026. Elevance Health stock is at EUR 367.05 on October 12, 2026.

Key points in brief

Barclays raised its Elevance Health price target from USD 457 to USD 469 on October 7, 2026.
Second-quarter 2026 revenue reached USD 49.83 billion and adjusted earnings per share were USD 7.45.
Elevance Health stock stood at EUR 367.05 at Lang & Schwarz on October 12, 2026 at 11:03 a.m. CEST.
Third-quarter 2026 results are scheduled for October 21, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health stock was at EUR 367.05 at Lang & Schwarz on October 12, 2026 at 11:03 a.m. CEST, while Markets Insider reported on October 7, 2026 that Barclays raised its Elevance Health target from USD 457 to USD 469 and kept an Overweight rating. The target revision came in a third-quarter earnings preview.

Three events shape the setup

On July 15, 2026, Elevance Health reported second-quarter revenue of USD 49.83 billion and adjusted earnings per share of USD 7.45, versus consensus of USD 6.21. MarketBeat also reported revenue of USD 49.83 billion against consensus of USD 48.88 billion, making the revenue comparison a concrete test for the next report.

On October 1, 2026, Elevance Health announced affiliated Medicare Advantage offerings for coverage beginning January 1, 2027. StockTitan reported that the plans include expanded support for chronic conditions and simplified benefit experiences.

What does the Medicare update mean?

The 2027 portfolio includes Dual Eligible Special Needs Plans and Chronic Condition Special Needs Plans, with coverage beginning January 1, 2027. That design gives the Medicare business a quantified calendar milestone, while the latest quarterly comparison shows why execution matters: adjusted earnings per share of USD 7.45 exceeded consensus by USD 1.24.

Medicare sentiment also carries a counter-factor. Investing.com reported on October 9, 2026 that Cantor Fitzgerald maintained an Overweight rating and a USD 450 target after Elevance's 2027 Medicare Stars rating fell to 47 percent from 54 percent in 2026. The contrast puts medical-cost management and government-plan performance at the center of the next earnings test.

Dates investors can measure

Medicare's Annual Enrollment Period runs from October 15 through December 7, 2026, for coverage beginning January 1, 2027, according to StockTitan. Elevance Health said on October 5, 2026 that it will release third-quarter results on October 21, 2026, at 6:00 a.m. EDT.

Elevance Health's NYSE quote closed at USD 412.70 on October 9, 2026, and its market capitalization was USD 89.5 billion on that date. The 52-week range was USD 274.84 to USD 436.24, leaving the stock below its yearly high while the euro reference price remained EUR 367.05.